论文信息 - The effect of zoledronic acid on serum osteoprotegerin in early stage multiple myeloma.

The effect of zoledronic acid on serum osteoprotegerin in early stage multiple myeloma.

We evaluated the effect of zoledronic acid (ZA) on serum levels of osteoprotegerin (OPG) and the ligand for receptor activator of nuclear factor kappaB (RANKL) in patients with smoldering myeloma. In treated subjects we found an increase of OPG accounting for an effect of ZA on osteoblast and/or bone marrow stromal cells together with the direct effect on osteoclasts.

[1] E. Terpos,et al. The role of markers of bone remodeling in multiple myeloma. , 2005, Blood reviews.

[2] P. Musto,et al. Pamidronate for early-stage, untreated myeloma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3] A. la Sala,et al. Pamidronate Reduces Skeletal Events but does not Improve Progression-free Survival in Early-stage Untreated Myeloma: Results of a Randomized Trial , 2003, Leukemia & lymphoma.

[4] L. Hofbauer,et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. , 2002, Biochemical and biophysical research communications.

[5] R. Bataille,et al. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. , 2001, Blood.

[6] G D Roodman,et al. Biology of osteoclast activation in cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7] S. Morony,et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[8] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.